{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:35:22Z","timestamp":1773210922661,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science Center in Poland","award":["DEC-2011\/03\/B\/NZ7\/00635"],"award-info":[{"award-number":["DEC-2011\/03\/B\/NZ7\/00635"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s40618-017-0779-7","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T03:00:56Z","timestamp":1510023656000},"page":"609-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective \u03b1-adrenoceptor antagonist"],"prefix":"10.1007","volume":"41","author":[{"given":"Magdalena","family":"Kota\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kulig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Marcinkowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Bednarski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Malawska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Zar\u0119ba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"key":"779_CR1","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735\u20132752","journal-title":"Circulation"},{"key":"779_CR2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","volume":"414","author":"P Zimmet","year":"2001","unstructured":"Zimmet P, Alberti KGMM, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414:782\u2013787","journal-title":"Nature"},{"key":"779_CR3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1291\/hypres.29.839","volume":"29","author":"G Grassi","year":"2006","unstructured":"Grassi G (2006) Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertens Res 29:11","journal-title":"Hypertens Res"},{"key":"779_CR4","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00125-005-1798-z","volume":"48","author":"G Grassi","year":"2005","unstructured":"Grassi G, Dell\u2019Oro R, Quarti-Trevano F, Scopelliti F, Seravalle G, Paleari F, Gamba PL, Mancia G (2005) Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 48:1359\u20131365","journal-title":"Diabetologia"},{"key":"779_CR5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/01.HYP.36.4.538","volume":"36","author":"G Grassi","year":"2000","unstructured":"Grassi G, Seravalle G, Dell\u2019Oro R, Turri C, Bolla GB, Mancia G (2000) Adrenergic and re ex abnormalities in obesity related hypertension. Hypertension 36:538\u2013542","journal-title":"Hypertension"},{"key":"779_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/341583","author":"AA Thorp","year":"2015","unstructured":"Thorp AA, Schlaich MP (2015) Relevance of sympathetic nervous system activation in obesity and metabolic syndrome. J Diabetes Res. \n                        https:\/\/doi.org\/10.1155\/2015\/341583\n                        \n                     (Article ID 341583)","journal-title":"J Diabetes Res"},{"key":"779_CR7","first-page":"13","volume":"62","author":"NK Kabra","year":"2014","unstructured":"Kabra NK (2014) Alpha blockers and metabolic syndrome. J Assoc Phys India 62:13\u201316","journal-title":"J Assoc Phys India"},{"key":"779_CR8","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.bmc.2015.03.009","volume":"348","author":"P Zar\u0119ba","year":"2015","unstructured":"Zar\u0119ba P, Dudek M, Lustyk K, Siwek A, Starowicz G, Bednarski M, Nowi\u0144ski L, Zygmunt M, Sapa J, Malawska B, Kulig K (2015) \u03b1-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-one. Bioorg Med Chem 348:2104\u20132111","journal-title":"Bioorg Med Chem"},{"key":"779_CR9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1152\/ajpendo.1993.264.4.E541","volume":"264","author":"Y Deshaies","year":"1993","unstructured":"Deshaies Y (1993) Postprandial plasma triacylglycerols under \u03b11-adrenergic blockade. Am J Physiol Endocrinol Metab 264:541\u2013547","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"779_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.numecd.2005.04.005","volume":"16","author":"AC Pessina","year":"2006","unstructured":"Pessina AC, Ciccariello L, Perrone F, Stoico V, Gussoni G, Scotti A, Muggeo M (2006) Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 16:137\u2013147","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"779_CR11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/ajcn\/55.1.219s","volume":"55","author":"M Lafontan","year":"2013","unstructured":"Lafontan M, Berlan M, Galitzky J, Montastruc J (2013) Alpha-2 adrenoceptors and lipid-mobilizing in lipolysis. Am J Clin Nutr 55:219\u2013225","journal-title":"Am J Clin Nutr"},{"key":"779_CR12","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/604989","author":"SN Yang","year":"2011","unstructured":"Yang SN, Pan M, Yang G, Cui X (2011) Subthreshold \u03b12-adrenergic activation counteracts glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion. Exp Diabetes Res. \n                        https:\/\/doi.org\/10.1155\/2011\/604989","journal-title":"Exp Diabetes Res"},{"key":"779_CR13","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1016\/j.ejmech.2009.04.028","volume":"44","author":"K Kulig","year":"2009","unstructured":"Kulig K, Sapa J, Nowaczyk A, Filipek B, Malawska B (2009) Design, synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxy-propyl]-3,3-diphenylpyrrolidin-2-one derivatives with antiarrhythmic, antihypertensive, and \u03b1-adrenolytic activity. Eur J Med Chem 44:3994\u20134003","journal-title":"Eur J Med Chem"},{"key":"779_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00210-010-0566-x","volume":"383","author":"J Sapa","year":"2011","unstructured":"Sapa J, Nowaczyk A, Kulig K (2011) Antiarrhythmic and antioxidant activity of novel pyrrolidin-2-one derivatives with adrenolytic properties. Naunyn Schmiedebergs Arch Pharmacol 383:13\u201325","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"779_CR15","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00044-010-9540-x","volume":"21","author":"A Nowaczyk","year":"2012","unstructured":"Nowaczyk A, Kulig K (2012) QSAR studies on a number of pyrrolidin-2-one antiarrhythmic arylpiperazinyls. Med Chem Res 21:373\u2013381","journal-title":"Med Chem Res"},{"key":"779_CR16","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.pharep.2014.02.014","volume":"66","author":"J Sapa","year":"2014","unstructured":"Sapa J, Zygmunt M, Kulig K, Malawska B, Dudek M, Filipek B, Bednarski M, Kusak A, Nowak G (2014) Evaluation of anticonvulsant activity of novel pyrrolidin-2-one derivatives. Pharmacol Reports 66:708\u2013711","journal-title":"Pharmacol Reports"},{"key":"779_CR17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/ardp.201500180","volume":"348","author":"P Zar\u0119ba","year":"2015","unstructured":"Zar\u0119ba P, Dudek M, Lustyk K, Siwek A, Starowicz G, Bednarski M, Nowi\u0144ski L, Zygmunt M, Sapa J, Malawska B, Kulig K (2015) Antiarrhythmic and \u03b1-adrenoceptor antagonistic properties of novel arylpiperazine derivatives of pyrrolidin-2-one. Arch Pharm (Weinheim) 348:861\u2013867","journal-title":"Arch Pharm (Weinheim)"},{"key":"779_CR18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejphar.2016.02.047","volume":"776","author":"M Dudek","year":"2016","unstructured":"Dudek M, Knutelska J, Bednarski M, Nowi\u0144ski L, Zygmunt M, Kazek G, Mordyl B, G\u0142uch-Lutwin M, Zar\u0119ba P, Kulig K, Sapa J (2016) Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity. Eur J Pharmacol 776:146\u2013155","journal-title":"Eur J Pharmacol"},{"key":"779_CR19","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s11011-015-9736-3","volume":"30","author":"M Dudek","year":"2015","unstructured":"Dudek M, Marcinkowska M, Bucki A, Olczyk A, Ko\u0142aczkowski M (2015) Idalopirdine\u2014a small molecule antagonist of 5-HT6 with therapeutic potential against obesity. Metab Brain Dis 30:1487\u20131494","journal-title":"Metab Brain Dis"},{"key":"779_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0141327","volume":"10","author":"M Dudek","year":"2015","unstructured":"Dudek M, Knutelska J, Bednarski M, Nowi\u0144ski L, Zygmunt M, Mordyl B, G\u0142uch-Lutwin M, Kazek G, Sapa J, Pytka K (2015) A comparison of the anorectic effect and safety of the alpha2-adrenoceptor ligands guanfacine and yohimbine in rats with diet-induced obesity. PLoS One 10:1\u201320","journal-title":"PLoS One"},{"key":"779_CR21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s11011-016-9840-z","volume":"3","author":"M Dudek","year":"2016","unstructured":"Dudek M, Kuder K, Ko\u0142aczkowski M, Olczyk A, \u017bmudzka E, Rak A, Bednarski M, Pytka K, Sapa J, Kie\u0107-Kononowicz K (2016) H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice. Metab Brain Dis 3:1023\u20131029","journal-title":"Metab Brain Dis"},{"key":"779_CR22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S1734-1140(10)70244-9","volume":"62","author":"K Kulig","year":"2010","unstructured":"Kulig K, Spieces C, Sapa J, Caspers C, Filipek B, Malawska B (2010) Synthesis and pharmacological evaluation of pyrrolidin-2-one derivatives as antiarrhythmic, antihypertensive and \u03b1-adrenolytic agents. Pharmacol Rep 62:68\u201385","journal-title":"Pharmacol Rep"},{"key":"779_CR23","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/oby.20581","volume":"21","author":"SK Janhunen","year":"2013","unstructured":"Janhunen SK, La Fleur SE, Adan RAH (2013) Blocking alpha2A adrenoceptors, but not dopamine receptors, augments bupropion-induced hypophagia in rats. Obesity 21:700\u2013708","journal-title":"Obesity"},{"key":"779_CR24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1742-7843.2011.00699.x","volume":"108","author":"V Fagerholm","year":"2011","unstructured":"Fagerholm V, Haaparanta M, Scheinin M (2011) \u03b12-adrenoceptor regulation of blood glucose homeostasis. Basic Clin Pharmacol Toxicol 108:365\u2013370","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"779_CR25","first-page":"482","volume":"215","author":"A Adefurin","year":"2016","unstructured":"Adefurin A, Darghosian L, Okafor C, Kawai V, Li C, Shah A, Wei WQ, Kurnik D, Stein CM (2016) \u03b12A adrenergic receptor genetic variation contributes to hyperglycemia after myocardial infarction. Can J Cardiol 215:482\u2013486","journal-title":"Can J Cardiol"},{"key":"779_CR26","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.2337\/db11-1516","volume":"61","author":"AH Rosengren","year":"2012","unstructured":"Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, Shigeto M, Zhang E, Almgren P, Ladenvall C, Axelsson AS, Edlund A, Pedersen MG, Jonsson A, Ramracheya R et al (2012) Reduced insulin exocytosis in human pancreatic \u03b2-cells with gene variants linked to type 2 diabetes. Diabetes 61:1726\u20131733","journal-title":"Diabetes"},{"key":"779_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3009934","volume":"6","author":"Y Tang","year":"2014","unstructured":"Tang Y, Axelsson AS, Sp\u00e9gel P, Andersson LE, Mulder H, Groop LC, Renstr\u00f6m E, Rosengren AH (2014) Genotype-based treatment of type 2 diabetes with an \u03b12A-adrenergic receptor antagonist. Sci Transl Med 6:1\u20139","journal-title":"Sci Transl Med"},{"key":"779_CR28","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.vascn.2011.03.003","volume":"64","author":"JJ Lynch","year":"2011","unstructured":"Lynch JJ, Castagn\u00e9 V, Moser PC, Mittelstadt SW (2011) Comparison of methods for the assessment of locomotor activity in rodent safety pharmacology studies. J Pharmacol Toxicol Methods 64:74\u201380. \n                        https:\/\/doi.org\/10.1016\/j.vascn.2011.03.003","journal-title":"J Pharmacol Toxicol Methods"},{"key":"779_CR29","doi-asserted-by":"crossref","first-page":"42958","DOI":"10.1074\/jbc.M207229200","volume":"277","author":"S Rodr\u00edguez-Cuenca","year":"2002","unstructured":"Rodr\u00edguez-Cuenca S, Pujol E, Justo R, Frontera M, Oliver J, Gianotti M, Roca P (2002) Sex-dependent thermogenesis, differences in mitochondrial morphology and function, and adrenergic response in brown adipose tissue. J Biol Chem 277:42958\u201342963","journal-title":"J Biol Chem"},{"key":"779_CR30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1476-5381.1989.tb11793.x","volume":"96","author":"DJ Bill","year":"1989","unstructured":"Bill DJ, Hughes IE, Stephens RJ (1989) The thermogenic actions of \u03b12-adrenoceptor agonists in reserpinized mice are mediated via a central postsynaptic \u03b12-adrenoceptor mechanism. Br J Pharmacol 96:133\u2013143","journal-title":"Br J Pharmacol"},{"key":"779_CR31","first-page":"103","volume":"8","author":"J G\u00f3mez-Ambrosi","year":"2001","unstructured":"G\u00f3mez-Ambrosi J, Fr\u00fchbeck G, Aguado M, Milagro FI, Margareto J, Mart\u00ednez AJ (2001) Divergent effects of an \u03b12-adrenergic antagonist on lipolysis and thermogenesis: interactions with a \u03b23-adrenergic agonist in rats. Int J Mol Med 8:103\u2013109","journal-title":"Int J Mol Med"},{"key":"779_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0706320","volume":"146","author":"S Bexis","year":"2008","unstructured":"Bexis S, Docherty JR (2008) Role of \u03b12A-adrenoceptors in the effects of MDMA on body temperature in the mouse. Br J Pharmacol 146:1\u20136","journal-title":"Br J Pharmacol"},{"key":"779_CR33","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1152\/ajpregu.00123.2002","volume":"283","author":"M Philipp","year":"2002","unstructured":"Philipp M, Brede M, Hein L (2002) Physiological significance of \u03b12-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 283:287\u2013295","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"779_CR34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejphar.2012.10.025","volume":"698","author":"M Kubacka","year":"2002","unstructured":"Kubacka M, Mogilski S, Filipek B, Marona H (2002) The hypotensive activity and \u03b11-adrenoceptor antagonistic properties of some aroxyalkyl derivatives of 2-methoxyphenylpiperazine. Eur J Pharmacol 698:335\u2013344","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"779_CR35","doi-asserted-by":"crossref","first-page":"e0152005","DOI":"10.1371\/journal.pone.0152005","volume":"11","author":"Q Yin","year":"2016","unstructured":"Yin Q, Yang C, Wu J, Lu H, Zheng Z, Zhang Y, Lv Z, Zheng X, Li Z (2016) Downregulation of \u03b2-adrenoceptors in isoproterenol-induced cardiac remodeling through HuR. PLoS One 11(4):e0152005","journal-title":"PLoS One"},{"key":"779_CR36","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/sj.bjp.0707637","volume":"153","author":"M Ciccarelli","year":"2008","unstructured":"Ciccarelli M, Santulli G, Campanile A, Galasso G, Cervero P, Altobelli GG, Cimini V, Pastore L, Piscione F, Trimarco B, Iaccarino G (2008) Endothelial \u03b11-adrenoceptors regulate neo-angiogenesis. Br J Pharmacol 153:936\u2013946","journal-title":"Br J Pharmacol"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-017-0779-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0779-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-017-0779-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T07:26:47Z","timestamp":1523863607000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-017-0779-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s40618-017-0779-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]}}}